Eisai receives positive CHMP opinion for Lecanemab in early Alzheimer’s disease
Eisai (ESAIY) and Biogen (BIIB) announced that a positive opinion has been received from the Committee for Medicinal Products for Human Use of ...
EMA recommends Leqembi for treatment of early Alzheimer’s disease
After re-examining its initial opinion, EMA’s human medicines committee, or CHMP, has recommended granting a marketing authorisation to Leqembi for treating mild cognitive impairment or mild dementia ...
CHMP issues positive recommendation for approval of lecanemab in the EU
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announces that EMA's Committee for Medicinal Products for Human Use (CHMP) has issued a positive recommendation regarding BioArctic's partner Eisai ...
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early ...
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and (Nasdaq: BIIB, Corporate headquarters: Cambridge, ...
TCTMD1 天
High Lp(a) Linked to ASCVD Risk Even When LDL Cholesterol Is Low
While statins can reduce LDL levels and ASCVD events, high Lp(a) poses an independent risk that will need attention, too.
business2 天
APOL 1 Genetic variant increases kidney disease risk in Ghana, Nigeria
A study led by a team of scientists in Ghana and Nigeria has revealed that nearly a third of Ghanaians-29.7% carry two copies of the Apolipoprotein LI (APOL1) gene variants increasing their risk of ...